耐药性仍然是胰腺癌治疗中的重大挑战。耐药细胞系的开发对于了解耐药性的潜在机制和开发新药以改善临床结果至关重要。在此，建立了一种源自中国患者的新型胰腺癌细胞系 PDAC-X1。 PDAC-X1的特征包括免疫表型、生物学、遗传学、分子特征和致瘤性。体外分析显示，PDAC-X1 细胞表现出上皮形态和细胞标志物（CK7 和 CK19），表达癌症相关标志物（E-cadherin、Vimentin、Ki-67、CEA、CA19-9），并产生胰腺癌样细胞悬浮培养的器官。体内分析表明，PDAC-X1细胞保持致瘤性，成瘤率100%。该细胞系表现出复杂的核型，以亚三倍体核型为主。此外，PDAC-X1细胞对多种药物表现出内在的多药耐药性，包括吉西他滨、紫杉醇、5-氟尿嘧啶和奥沙利铂。总之，PDAC-X1 细胞系已经建立并进行了表征，代表了一个有用且有价值的临床前模型，可用于研究耐药性的潜在机制并开发新的药物疗法以改善患者的治疗结果。© 2024。作者。

Drug resistance remains a significant challenge in the treatment of pancreatic cancer. The development of drug-resistant cell lines is crucial to understanding the underlying mechanisms of resistance and developing novel drugs to improve clinical outcomes. Here, a novel pancreatic cancer cell line, PDAC-X1, derived from Chinese patients has been established. PDAC-X1 was characterized by the immune phenotype, biology, genetics, molecular characteristics, and tumorigenicity. In vitro analysis revealed that PDAC-X1 cells exhibited epithelial morphology and cell markers (CK7 and CK19), expressed cancer-associated markers (E-cadherin, Vimentin, Ki-67, CEA, CA19-9), and produced pancreatic cancer-like organs in suspension culture. In vivo analysis showed that PDAC-X1 cells maintained tumorigenicity with a 100% tumor formation rate. This cell line exhibited a complex karyotype, dominated by subtriploid karyotypes. In addition, PDAC-X1 cells exhibited intrinsic multidrug resistance to multiple drugs, including gemcitabine, paclitaxel, 5-fluorouracil, and oxaliplatin. In conclusion, the PDAC-X1 cell line has been established and characterized, representing a useful and valuable preclinical model to study the underlying mechanisms of drug resistance and develop novel drug therapeutics to improve patient outcomes.© 2024. The Author(s).